Technical Data
Tumor Necrosis Factor Receptor Associated Factor 3 (TNF Receptor Associated Factor 3, TNF Receptor-associated Factor 3, TRAF 3, TRAF3, TRAF-3, CD40-associated Protein 1, CAP1, CAP-1, CD40 Binding Protein, CD40 BP, CD40BP, CD40 Receptor-associated Factor 1
MIP-T3 (microtubule-interacting protein associated with TRAF3) was originally identified in a yeast-two hybrid screen for proteins that interact with the tumor necrosis factor receptor (TNFR)-associated factor 3 (TRAF3). As a microtubule binding protein, MIP-T3 has been found to mediate the binding of DISC1 (disrupted-in-schizophrenia 1) to microtubules. MIP-T3 has also been shown to associate with IL13 receptor alpha (IL-13Ralpha1) and function as an inhibitor of IL-13 signaling. Recently, studies of the C. elegans homolog of MIP-T3 (DYF-11) have revealed that MIP-T3 is critical to cilium development; and in mammalian cells, MIP-T3 has been found to localize to basal bodies and cilia. Alternate names for MIP-T3 include TRAF3IP1, interleukin 13 receptor alpha1-binding protein 1, and TRAF3-interacting protein.

Suitable for use in Western Blot and Immunoprecipitation. Other applications not tested.

Recommended Dilution:
Western Blot 1:2000-1:10000,
immunoprecipitation 2-5ug/mg lysate
Optimal dilution determined by the researcher.

Storage and Stability:
May be stored at 4C. For long-term storage, aliquot and store at 4C. Do not freeze. Aliquots are stable for at least 3 months. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer.
PabIgGAffinity Purified
100ul4C Do Not FreezeBlue IceHumanRabbit
The epitope recognized by this antibody maps to a region between residue 619 to 669 of human microtubule interacting protein that associates with TNF receptor-associated factor 3.
Purified by immunoaffinity chromatography.
Supplied as a liquid in TBS, 0.1% BSA, 0.09% sodium azide.
Recognizes human TRAF-3.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.